-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 6, Hengrui Medicine announced that the company and Shanghai Yingli had received the approval of the State Drug Administration for the issuance of the "Drug Clinical Trial Approval Letter" for YY-20394 tablets, and agreed to carry out YY-20394 combined with MIL62 in relapse.
YY-20394 is a class 1 innovative drug developed by Shanghai Yingli, which is a highly selective inhibitor of PI3Kδ (phosphatidylinositol-3-kinase δ isoform)
After inquiries, there are currently 4 PI3Kδ inhibitors abroad (some products also have high inhibitory activity against other PI3K subtypes) approved for marketing, namely Idelalisib (Gilead Sciences, trade name Zydelig), Duvelisib (Verastem, trade name Copiktra) , Copanlisib (Bayer Pharmaceuticals, trade name Aliqopa) and Umbralisib (TG Therapeutics, trade name Ukoniq)
MIL62 is a glycosylated humanized type II anti-CD20 monoclonal antibody developed by Beijing Tianguangshi Biotechnology Co.
After inquiries, as of now, only one third-generation anti-CD20 mAb has been approved for marketing in the world, which is Obinutuzumab (Roche, trade name Gazyva), which has been approved for marketing in China
There are multiple regulatory pathways for the proliferation, survival and drug resistance of malignant B cells.
